Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.

ABSTRACT:

Importance

The use of immune checkpoint inhibitors (ICIs) is increasing. Little is known about the frequency of late-onset immune-related adverse events (irAEs) and the patient-specific risk factors associated with their development.

Objectives

To assess the incidence of persistent or de novo late-onset irAEs requiring hospitalization and identify patient factors associated with risk of late-onset irAEs.

Design, setting, and participants

This retrospective observational cohort study conducted from January 2011 to October 2022 included patients who received ICIs and were hospitalized with irAEs at an academic medical center. Exclusion criteria included ICI therapy outside of the hospital system and no irAE diagnosis during admission. Data were analyzed from November 15

SUBMITTER: Durbin SM 

PROVIDER: S-EPMC11950896 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature